Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours. - Wikidata - awgldk - TriplyDB

Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours.

Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours.

http://www.wikidata.org/entity/Q33658544

about

A novel fully human antitumour immunoRNase targeting ErbB2-positive tumours.A novel fully human antitumor immunoRNase resistant to the RNase inhibitor Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells.Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge.Novel antibody-based proteins for cancer immunotherapy.Effects of a human compact anti-ErbB2 antibody on gastric cancer.Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors.A novel ErbB2 epitope targeted by human antitumor immunoagents

P2860

Q35034584-CD88C135-5ED5-4344-8138-55AAEED7935A Q36610794-F413A6AC-A59B-4E0B-B84D-53F2387E402D Q37586081-E7AE8D33-F83D-4739-AEC2-A7E3B213F1B2 Q37973320-DFFBD170-6853-4A94-AF87-22063FEB5FB0 Q38161370-8C97CCDA-5539-4FA2-B367-93E787E5A35C Q39185414-B3171165-3A27-46A7-A2ED-AFE63CBB14A5 Q39468098-EE13FEE3-884F-4CFE-9601-7111D1CE6320 Q57628597-D83CC8EC-ABAE-4DC8-8F4D-61048140C27B

P2860

Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours.

http://www.wikidata.org/entity/Q33658544

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours.

@ast

Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours.

@en

type

label

Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours.

@ast

Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours.

@en

prefLabel

Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours.

@ast

Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours.

@en

P1433

Q33658544-778D86B1-5438-445C-8A6E-DC490B016CF5

P1476

Q33658544-588EF3BF-F91C-48F0-B410-F0EACE2D0BFB

P2093

Q33658544-035EE016-6446-4351-9903-551107826685

Q33658544-1FFBA268-316F-4A03-BB89-1C1F51F4ED93

Q33658544-73387CCA-8D7F-4DE9-A05A-5546574A8517

Q33658544-9BFDC9B6-C646-4533-8700-E27B9557411B

Q33658544-B086ACAD-09AC-4AA8-821A-3FED2F1B9636

Q33658544-BAB71F7F-F256-4274-913A-D78B44538930

Q33658544-C3771FF5-3569-4668-9775-6683090EDE6B

Q33658544-DB3FDC14-BD5E-4E3F-A431-26B348FF0CFB

Q33658544-F6D75E4F-CEE3-4901-A9C7-8D06D6A40A5C

P2860

Q33658544-059B6755-13D8-4C91-BE17-8496A57BF5ED

Q33658544-0AE4BCF6-DA56-46B7-A15B-6CBA2493B52D

Q33658544-0D86AED0-292C-41C7-8B4B-0995FF15CB8C

Q33658544-22489D43-6156-4DA4-BCDD-5113A9E4B93B

Q33658544-2D8749E9-169E-43DB-A6BD-B82F5C5CCFAD

Q33658544-40230475-086E-4186-815B-CDB55041C89B

Q33658544-5B7EE1D8-AA9D-4B96-8329-71893FB76BC1

Q33658544-67BE6507-6091-404F-A1C2-B0B68453338B

Q33658544-74D34D08-0B11-4830-8CD9-6790EEAD7629

Q33658544-7860671E-527E-4617-9F55-77AC0A7E5408

P2888

Q33658544-F29D9DB9-E7ED-425C-AB6E-E0F9D12BB950

P304

Q33658544-CD11AC37-A0A7-4AD1-A3DA-3BDA2ABE38C0

P31

Q33658544-38E4C31B-3883-44FB-8914-1841568275B7

P356

Q33658544-7538B256-9636-408C-96EB-ACF342692FA8

P407

Q33658544-EDB9E40C-F480-4DEF-8C9D-FF513BD67C7E

P433

Q33658544-15B0B305-3854-437D-9F0B-7328DB080B10

P478

Q33658544-1A7F2FD3-3839-4C2B-8506-925CF6CA01C8

P577

Q33658544-9BFDFD9D-0692-4611-BC3B-A432FB774999

P5875

Q33658544-4653FD47-1F4C-4974-BEC5-85761ED0B5D8

P6179

Q33658544-1041A5F3-9D8B-4044-9CAF-74BFE4F52347

P698

Q33658544-1FC1797F-4192-4B07-ADD9-D8F1EACFE5C5

P932

Q33658544-7BF3D3B8-3E7D-4980-8251-934D13AA066D

P356

P1433

British Journal of Cancer

P1476

Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours.

@en

P2093

C De Lorenzo

http://www.w3.org/2001/XMLSchema#string

G D'Alessio

http://www.w3.org/2001/XMLSchema#string

G Tortora

http://www.w3.org/2001/XMLSchema#string

P Laccetti

http://www.w3.org/2001/XMLSchema#string

R Bianco

http://www.w3.org/2001/XMLSchema#string

R Cozzolino

http://www.w3.org/2001/XMLSchema#string

R Rosa

http://www.w3.org/2001/XMLSchema#string

T Gelardi

http://www.w3.org/2001/XMLSchema#string

V Damiano

http://www.w3.org/2001/XMLSchema#string

P2860

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

A new human antitumor immunoreagent specific for ErbB2.

Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).

Mechanism of action of anti-HER2 monoclonal antibodies.

Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy

Herceptin: mechanisms of action and resistance.

Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin.

P2888

P304

513-519

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6605499

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40850783

http://www.w3.org/2001/XMLSchema#string

P6179

1018000700

http://www.w3.org/2001/XMLSchema#string

P698

20051960

http://www.w3.org/2001/XMLSchema#string

P932

2822937

http://www.w3.org/2001/XMLSchema#string